Floatz logo

306 assets in B-Cell Non-Hodgkin Lymphoma

Therapeutic assets addressing B-Cell Non-Hodgkin Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Ipilimumab
B-Cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer CenterP2B (60)
JS203
B-Cell Non-Hodgkin Lymphoma
Shanghai Junshi Bioscience Co., Ltd.P2B (60)
Nivolumab
B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P2B (60)
Recombinant Human Hyaluronidase
B-Cell Non-Hodgkin Lymphoma
Academic and Community Cancer Research UnitedP2B (60)
Selinexor
B-Cell Non-Hodgkin Lymphoma
Samsung Medical CenterP2B (60)
Vorinostat
B-Cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer CenterP2B (60)
yy-20394
B-Cell Non-Hodgkin Lymphoma
Jiangsu HengRui Medicine Co., Ltd.P2B (60)
Bendamustine
B-Cell Non-Hodgkin Lymphoma
Swiss Cancer InstituteP2B (59)
Btk-In-24
B-Cell Non-Hodgkin Lymphoma
Nurix Therapeutics, Inc.P3B (59)
Chimeric Antigen Receptor Modified T Cells Infusion
B-Cell Non-Hodgkin Lymphoma
Shanxi Bethune HospitalP2B (59)
Entecavir
B-Cell Non-Hodgkin Lymphoma
Sun Yat-sen UniversityP3B (59)
cd22 car-transduced t cells
B-Cell Non-Hodgkin Lymphoma
Minsk Scientific-Practical Center for Surgery, Transplantation and HematologyP1/2B (58)
Decitabine
B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P1/2B (58)
Jcar-017 Cd19-Specific Chimeric Antigen Receptor
B-Cell Non-Hodgkin Lymphoma
Lyell Immunopharma, Inc.P3B (58)
Tafasitamab
B-Cell Non-Hodgkin Lymphoma
Brown UniversityP2B (58)
Tocilizumab
B-Cell Non-Hodgkin Lymphoma
Hoffmann-La RocheP1/2B (58)
Capivasertib
B-Cell Non-Hodgkin Lymphoma
AstraZenecaP2B (57)
Lornoxicam
B-Cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow UniversityP2B (57)
rn1701
B-Cell Non-Hodgkin Lymphoma
The First Affiliated Hospital with Nanjing Medical UniversityP1/2B (57)
cd19/cd20 dual-car-t cells
B-Cell Non-Hodgkin Lymphoma
Beijing Tsinghua Chang Gung HospitalP1/2B (56)
cd19 t-hank
B-Cell Non-Hodgkin Lymphoma
ImmunityBio, Inc.P2CCC (55)
Hydrocortisone
B-Cell Non-Hodgkin Lymphoma
Therapeutic Advances in Childhood Leukemia ConsortiumP2CCC (55)
Anakinra
B-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer CenterP2CCC (54)
Epcoritamab
B-Cell Non-Hodgkin Lymphoma
Mwanasha Merrill, MDP2CCC (54)
Rondecabtagene Autoleucel
B-Cell Non-Hodgkin Lymphoma
Lyell Immunopharma, Inc.P3CCC (54)
Zilovertamab
B-Cell Non-Hodgkin Lymphoma
Oncternal Therapeutics, IncP3CCC (54)
Allogeneic Natural Killer (Nk) Cells Derived From Umbilical Cord Blood, Transduced With A Moloney Murine Leukaemia Virus (Mmlv)-Based Retroviral Vector Encoding Inducible Caspase-9 Comprising Human Caspase-9 Fused To A Human Fk506 Binding Protein Variant (Fkbp-F36V), A Chimeric Antigen Receptor (Car) Targeting Cd19 Fused To Cd28 And Cd3 Zeta Signaling Domains, And Secretable Human Interleukin 15 (Il-15), Linked Together By T2A And E2A Self-Cleaving Peptide Sequences, Respectively, Under The Control Of The 5' Long Terminal Repeat (Ltr) Mmlv Promoter; The Construct Is Flanked By 5' And 3' Ltrs And Contains An Mmlv ? Packaging Signal And Partial Pol Gene. The Vector Is Pseudotyped With The Envelope Glycoprotein Of Gibbon Ape Leukaemia Virus (Galv). The Cord Blood Mononuclear Cells Are Treated With Antibody-Coated Magnetic Beads Against Cd19, Cd3 And Cd14 To Remove B Cells, T Cells, And Monocytes. The Purified Nk Cells Are Then Activated Using An Irradiated Antigen Presenting Cell Line (Apc) In The Presence Of Growth Medium Containing Il-2. Further Depletion Of Residual Cd3+ T Cell May Be Performed Using Antibody-Coated Magnetic Beads. The Substance Contains >80% Nk Cells (Cd45+Cd3-Cd56+), Of Which With >21% Are Car Positive, And Secrete Il-15.
B-Cell Non-Hodgkin Lymphoma
TakedaP2CCC (53)
Axi-Cel
B-Cell Non-Hodgkin Lymphoma
M.D. Anderson Cancer CenterP2CCC (53)
Fludeoxyglucose
B-Cell Non-Hodgkin Lymphoma
Mwanasha Merrill, MDP2CCC (53)
Human Cd19Targeted T Cells
B-Cell Non-Hodgkin Lymphoma
Hrain Biotechnology Co., Ltd.P2CCC (53)
Linperlisib
B-Cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Xiamen UniversityP2CCC (53)
men1703
B-Cell Non-Hodgkin Lymphoma
Ryvu Therapeutics SAP2CCC (53)
Mitoxantrone
B-Cell Non-Hodgkin Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyP2CCC (53)
Ontorpacept
B-Cell Non-Hodgkin Lymphoma
Mayo ClinicP2CCC (53)
Palbociclib
B-Cell Non-Hodgkin Lymphoma
Alliance Foundation Trials, LLC.P2CCC (53)
Polymer-Lipid Nanoparticle-Mediated Delivery Of Cd19/Cd20 Dual-Targeting Invivocar1920 Mrna For Car-T Cell Immunotherapy
B-Cell Non-Hodgkin Lymphoma
Daihong LiuP2CCC (53)
Tislelizumab
B-Cell Non-Hodgkin Lymphoma
Ruijin HospitalP2CCC (53)
Tucidinostat
B-Cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Xiamen UniversityP2CCC (53)
Azacytidine
B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P1/2CCC (52)
Diphenhydramine
B-Cell Non-Hodgkin Lymphoma
Institute of Hematology & Blood Diseases Hospital, ChinaP2CCC (52)
Eltrombopag
B-Cell Non-Hodgkin Lymphoma
Tel-Aviv Sourasky Medical CenterP2CCC (52)
Human Signal Regulatory Protein Alpha (Sirp Alpha Variant V2 Extracellular D1 Domain, Sirp Alpha V2D1) Fragment 31-163, Comprising The First Two Extracellular Loops Of The D1 Domain, [N<Sup>110</Sup>>A<Sup>80</Sup>]-Variant, Anti-(Human Cd47, Integrin Associated Protein (Iap)) (1-133 In The Current Sequence) Fused Via A (G4S) 2 Peptide Linker (134-143) To Gamma 1 Heavy Chain (144-594) [Vh (Mus Musculus Ighv1-12*01 -(Ighd) -Ighj1*01, Cdr-Kabat [5.17.12](174-178.193-209.242-253)) (144-264) -Homo Sapiens Ighg1*03(Ch1 (265-362), Hinge (363-377), Ch2 S<Sup>445</Sup>>A, E<Sup>480</Sup>>A, K <Sup>481</Sup>>A (378-487), Ch3 (488-592), Chs (593-594)) (265-594)], (367-213')-Disulfide With Kappa Light Chain (1'-213') [V-Kappa (Mus Musculus Igkv4-72*01 -Igkj1*01, Cdr-Kabat [10.7.9] (24'-33'.49'-55'.88'-96')) (1'-106') -Homo Sapiens Igkc*01 (107'-213')]; Dimer (373-373'':376-376'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1, Glycoform Alfa
B-Cell Non-Hodgkin Lymphoma
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.P1/2CCC (52)
Pemigatinib
B-Cell Non-Hodgkin Lymphoma
University of UtahP2CCC (52)
cd19/cd22-bispecific car-t cells
B-Cell Non-Hodgkin Lymphoma
Beijing Tongren HospitalP2CCC (51)
Human Peripheral Blood Leukocytes
B-Cell Non-Hodgkin Lymphoma
The First Affiliated Hospital of Soochow UniversityP2CCC (51)
Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer
B-Cell Non-Hodgkin Lymphoma
National Cancer Institute (NCI)P2CCC (51)
Sepantronium
B-Cell Non-Hodgkin Lymphoma
Cothera Bioscience, IncP2CCC (51)
TQB3702
B-Cell Non-Hodgkin Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.P2CCC (51)
Tretinoin
B-Cell Non-Hodgkin Lymphoma
Ruijin HospitalP2CCC (51)
Valemetostat
B-Cell Non-Hodgkin Lymphoma
The Lymphoma Academic Research OrganisationP2CCC (51)
Showing 51 to 100 of 306 assets
PreviousPage 2 of 7Next